PD-1/PD-L1抑制剂在NSCLC治疗的进展与挑战
摘要
关键词
全文:
PDF参考
[1]Liu L M. Future 10-year outlook for integrated traditional Chinese and Western medicine oncology [J]. Chinese Journal of Integrated Traditional and Western Medicine,2011,31(07):870-872.
[2]Ding R M, Wang P, Ma L J, et al. Effect of Qijiao Shengbai capsule on leukopenia and quality of life in lung cancer patients undergoing radiotherapy [J]. Modern Oncology,2016,24(03):400-403.
[3]Khan N A P, Blais N, Gaudreau P O, et al. Immunotherapy comes of age in lung cancer [J]. Clin Lung Cancer,2017,18(1):13-12.
[4]Zhou Y L, Zhang Y C, Liao D H, et al. Research progress of PD-1/PD-L1 inhibitors in non-small cell lung cancer after EGFR-TKIs treatment failure [J]. Central South Pharmacy,2021,19(10):2104-2110.
[5]Chen D S, Irving B A, Hodi F S. Molecular pathways: next-generation immunotherapy - inhibiting programmed death-ligand 1 and programmed death-1 [J].ClinCancerRes,2012;18(24):6580-7.
[6]Chikuma S. Basics of PD-1 in self-tolerance, infection, and cancer immunity [J]. Int J Clin Oncol,2016;21(3):448-55.
[7]Zhang M. Research on comprehensive tumor immunotherapy based on PD-1/PD-L1 blockade [D]. Shanghai Ocean University, 2021.DOI: 10.27314/d.cnki. gsscu.2021.000554.
[8]Efremova M, Rieder D, Klepsch V, et al. Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution [J]. Nat Commun,2018,9(1):32.
[9]Neumann M, Murphy N, Seetharamu N. The evolving role of PD-L1 inhibition in non-small cell lung cancer: a review of durvalumab and avelumab [J]. Cancer Med J,2022,5(1):
[10]Nadal X E, Massuti B, Dómine M, et al. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors [J]. Cancer Immunol Immunother,2019,68(3):341-352.
[11]Antonia S J, Borghaei H, Ramalingam S S, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis [J]. Lancet Oncol,2019,20(10):1395-1408.
[12]Wang Y C, Xu Y H, Li H W, et al. Research progress of PD1/PD-L1 immune checkpoint inhibitors in the treatment of non-small cell lung cancer [J]. Journal of Jilin University (Medical Edition),2019,45(4):965-970.
[13]Zhou J, Wu Q, Xu F, et al. Clinical research progress of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in small cell lung cancer [J]. Chinese Clinical Oncology,2021,26(7):649-656.
[14]Lin C, Chen X, Liu J N, et al. Research progress of PD-1/PD-L1 signaling pathway in immune escape and treatment of non-small cell lung cancer [J]. Chinese Journal of Lung Cancer,2014,17(10):734-740.
[15]Santarpia M, Gonzalez-Cao M, Viteri S, et al. Programmed cell death protein-1/programmed cell death ligand pathway inhibition and predictive biomarkers: Understanding transforming growth factor-beta role [J]. Transl Lung Cancer Res,2015,4(6):728-742.
[16]Alvarez J G B, Gonzalez-Cao M, Karachaliou N, et al. Advances in immunotherapy for treatment of lung cancer [J]. Cancer Biol Med,2015,12(3):209-222.
[17]MORENO B H, PARISI G, ROBERT L, et al. Anti-PD-1 therapy in melanoma [J]. Seminars Oncol, 2015,42(3):466-473.
[18]王佳慧,陈公琰.基于PD-1/PD-L1抑制剂的非小细胞肺癌免疫治疗预测标志物的研究进展[J].现代肿瘤医学,2021,29(10):1822-1825.
[19]刘巍,王丽娜,张黎明,等.程序性死亡受体1/程序性死亡受体配体1抑制剂在非小细胞肺癌中的研究进展[J].癌症进展,2023,21(11):1176-1179,1191.DOI:10.11877/j.issn. 1672-1535.2023.21.11.04.
[20]TOPALIAN S L, HODI F S, BRAHMER J R, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer [J].New Engl J Med,2012,366(26):2443-2454.
[21]Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer [J]. N Engl J Med,2015,373(17):1627-1639.
[22]Brahmer J, Reckamp K L, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer [J]. N Engl J Med,2015,373(2):123-135.
[23]GARON E B, RIZVI N A, HUI R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer [J]. New Engl J Med,2015,372(21):2018-2028.
[24]LANGER C J, GADGEEL S M, BORGHAEI H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study [J]. Lancet Oncol,2016,17(11):1497-1508.
[25]廖玮,唐景财,刘维,蒋璇,黎丽.PD-1/PD-L1免疫检查点抑制剂在肺癌治疗中的临床研究进展分析[J].中国科技期刊数据库医药,2024(2):0095-0098.
[26]Rocco D, Dell'Agrava A L, Battisti R, et al. The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced non-small cell lung cancer [J]. Expert Opin Biol Ther,2021,21(3):303-309.
[27]GALON J, BRUNI D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies [J]. Nat Rev Drug Discov,2019,18(3):197-218.
[28]WARNER A B, POSTOW M A. Combination controversies: checkpoint inhibition alone or in combination for the treatment of melanoma? [J]. Oncology (Williston Park),2018,32(5):228-234.
[29]CURRAN M A, MONTALVO W, YAGITA H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors [J]. Proc Natl Acad Sci USA, 2010,107(9):4275-4280.
[30]READY N, HELLMANN M D, AWAD M M, et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers [J]. J Clin Oncol,2019,37(12):992-1000.
[31]Sugawara S, Lee J S, Kang J H, et al. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer [J]. Ann Oncol,2021,32(9):1137-1147.
[32]Moya-Horno I, Viteri S, Karachaliou N, et al. Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC) [J]. Ther Adv Med Oncol,2018;10:1758834017745012.
[33]邱鲁鹏,孙卓雅,赵晓,等.抗血管生成药物联合免疫检查点抑制剂治疗非小细胞肺癌的作用机制及临床应用进展[J].解放军医学院学报,2022,43(12):1288-1292.
(0 摘要 Views, 0 PDF Downloads)
Refbacks
- 当前没有refback。